Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients

Abstract The clinical impact of molecular ontogeny in acute myeloid leukemia (AML) was defined in patients treated with intensive chemotherapy. In a cohort of 314 newly diagnosed AML patients, we evaluated whether molecular ontogeny subgroups have differential benefit of venetoclax (VEN) added to hypomethylating agents (HMA). In secondary ontogeny ( n = 115), median overall survival (OS)(14.1 vs . 6.9 months, P = 0.0054), composite complete remission (cCR 61% vs . 18%, P < 0.001) and allogeneic hematopoietic stem cell transplant (alloHCT) (24% vs . 6%, P = 0.02) rates were better in patients treated with HMA + VEN vs . HMA. In contrast, in TP53 AML( n = 111) median OS (5.7 vs . 6.1, P = 0.93), cCR (33% vs. 37%, P = 0.82) and alloHCT rates (15% vs . 8%, P = 0.38) did not differ between HMA + VEN vs. HMA. The benefit of VEN addition in the secondary group was preserved after adjustment for significant clinicopathologic variables (HR 0.59 95% CI 0.38–0.94, P = 0.025). The OS benefit of HMA + VEN in secondary ontogeny was similar in those with vs . without splicing mutations ( P = 0.92). Secondary ontogeny AML highlights a group of patients whose disease is selectively responsive to VEN added to HMA and that the addition of VEN has no clinical benefit in TP53 -mutated AML.